03309 C-MER MEDICAL
- 2.480
- -0.010-0.40%
C-MER MEDICAL News
Hima Medical received an increase in shareholding of 0.348 million shares of the company's stock from the CEO and executive director, Lin Shunchao.
Sihuan Pharmaceutical Holdings Group Ltd. (03309) announced that the board of directors of the company was informed by the company's chairman, CEO and executive director, Lin Shunchao, that he had purchased a total of 0.348 million shares of the company's stock in the market on July 22, 2024, at a total cost of HKD 0.9203 million, equivalent to an average price of about HKD 2.64 per share and accounting for approximately 0.028% of the company's issued share capital.
Hima Medical (03309.HK) received Chairman, CEO and Executive Director Lin Shunchao's shareholding of 0.358 million shares.
Hithink RoyalFlush announced on July 19th that the Board of Directors was informed by the Chairman, CEO and Executive Director, Lin Shunchao, that he had purchased a total of 0.358 million shares of the company on the market since July 18, 2024, at a total cost of HKD 949,940, which is an average price of approximately HKD 2.65 per share and accounts for approximately 0.029% of the company's issued share capital.
Hima Medical received an increase in shareholding of 0.792 million shares by the Executive Director and CEO Lin Shunchao.
Hima Medical (03309) announced that the Board of Directors (Board of Directors) of the company has been informed by Dr. Lin Shunchao, the chairman, CEO and executive director of the company, that he has purchased a total of 0.792 million shares of the company's stock on the market since July 15, 2024, at a total cost of HKD 2.077 million, with an average price of about HKD 2.62 per share (for the purchase from July 15 to July 17), accounting for approximately 0.063% of the company's issued share capital. Prior to the purchase from July 15 to July 17, Dr. Lin, together with Hima Group Limited (the company's controlling shareholder)
Express News | C-Mer Eye Care - CEO Purchased 792,000 Shares of Co for HK$2.1 Mln
C-MER Medical Renews Lease for Shenzhen Eye Hospital Property
Hima Medical (03309.HK): Shenzhen Hima Hospital Renews Lease.
On July 15th, Gelonhui reported that the existing lease agreement for the Shenzhen property where Hima Medical's ophthalmic hospital operates will expire on July 31, 2024. On July 15, 2024, Shenzhen Hima Hospital entered into a new lease agreement, whereby Shenzhen Maida and Shenzhen Hima Hospital extended the term of the lease for Shenzhen Property for 36 months. Based on the new lease agreement effective from August 1, 2024, the Group will recognize the lease as the right-of-use asset. Based on the preliminary assessment by the company's management (which has not been reviewed or audited by the company's auditors), Shenzhen Property will ...
On July 12th, Xima Medical (03309.HK) spent HKD 0.491 million to buy back 0.186 million shares.
On July 12th, Gelonhui announced that Xima Medical (03309.HK) will spend 0.491 million Hong Kong dollars to buy back 0.186 million shares on July 12, 2024, with a repurchase price of HKD 2.64 per share.
C-MER Medical Repurchases to Cancel 11 Million Shares, Purchases 15 Million Shares for Award Scheme
Hima Medical proposes to conduct a share repurchase in 2024 and a stock reward plan purchase in 2024.
Hema Medical (03309) announced that it has spent a total of 87.9 million Hong Kong dollars between September 7, 2023 and July 11, 2024 to repurchase 10.998 million shares in the market, with a total purchase amount of 41.6 million Hong Kong dollars. These shares have been cancelled. In addition, the company purchased 15.136 million shares in the market for a total purchase amount of 46.3 million Hong Kong dollars for the trust to hold for the benefit of selected participants according to the rules and terms and conditions of the 2022 share incentive plan and the trust deed until they vest.
C-mer Eye (03309.HK) plans to purchase shares based on the 2022 share incentive plan.
On July 11th, Gleannlo announced that C-mer Eye (03309.HK) has applied a total of HKD 87.9 million between September 7, 2023 and July 11, 2024, consisting of (1) repurchasing 10,998,000 shares on the market, with a total purchase amount of HKD 41.6 million, and these shares have been cancelled afterwards; (2) purchasing 15,136,000 shares on the market for the trustee according to the 2022 share incentive plan, with a total purchase amount of HKD 46.3 million. The trustee acquired these shares in accordance with the terms and conditions of the plan and the trust agreement and within its limits.
C-MER Eye Care Changes Name to C-MER Medical Holdings
C-mer Eye (03309.HK) plans to rename as "C-mer Medical".
On June 24, Gelonhui reported that C-MER Eye Care Holdings Limited (03309.HK) announced that the company's English name has been changed to C-MER Medical Holdings Limited, and its Chinese-English dual foreign name has been changed to Xi Ma Medical Holdings Limited. The English stock abbreviation for trading on the Hong Kong Stock Exchange will be changed from "C-MER EYE" to "C-MER MEDICAL", and the Chinese stock abbreviation...
C-MER Eye Care Sells Stake in Israel-Based Belkin Vision to Alcon
Hima Ophthalmology subsidiary has sold its shares in Belkin Vision Ltd., to Alcon
Hima Ophthalmology (03309) announced that Hong Kong (International) Eye Care Group Co., Ltd. (Hong Kong Ophthalmology), a wholly-owned subsidiary of the company, has sold it to Belkin Vision Ltd. (Sale Company) shares are vested in Alcon Pharmaceuticals Ltd (Alcon). Its book value as at 31 December 2023 was HK$23.3 million, and classified as a financial asset that includes other full income at fair value. The costs are as follows: the fixed cash cost at completion is approximately US$6.4 million; and possibly the cost does not exceed US$17 million,
Hima Ophthalmology (03309) subsidiary has sold its shares in Belkin Vision Ltd., to Alcon
Zhitong Financial App News, Hima Ophthalmology (03309) announced that Hong Kong (International) Ophthalmology Group Limited (Hong Kong Ophthalmology), a wholly-owned subsidiary of the company, has sold its shares in Belkin Vision Ltd. (the selling company) to Alcon Pharmaceuticals Ltd. (Alcon). Its book value as of December 31, 2023 was HK$23.3 million, and classified as a financial asset that includes other full income at fair value. The cost is as follows: The fixed cash cost at completion is approximately 6.4 million yuan. dollars; and possibly no more than
C-MER EYE: Annual Report 2023
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Xima Ophthalmology (03309) announced annual results. Profit attributable to shareholders was HK$61.98 million, turning a year-on-year loss into a profit
According to the Zhitong Finance App, Xima Ophthalmology (03309) announced annual results for the year ended December 31, 2023, with revenue of HK$1,924 million, up 11.1% year on year; the company's equity holders should have accounted for the profit of HK$61.98 million during the year, while the same period in 2022 recorded a loss of HK$21.875 million and a profit of HK4.94 cents per share. According to the announcement, total revenue in 2023 was HK$1,924 million, a slight increase of 11.1% over 2022, due to core medical service revenue in 2023 (including provision of ophthalmology services, provision of dental and other medical services, and sales
C-MER EYE: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
C-mer Eye Care Holdings Foresses HK$65 Million in 2023 Profit
Analysis
Price Target
No Data
